Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

INTRODUCTION: Clinical trials of new treatments for rheumatoid arthritis (RA) typically require subjects to have an elevated acute phase reactant (APR), in addition to tender and swollen joints. However, despite the elevation of individual components of the Clinical Disease Activity Index (CDAI) (te...

Descripción completa

Detalles Bibliográficos
Autores principales: Kay, Jonathan, Morgacheva, Olga, Messing, Susan P, Kremer, Joel M, Greenberg, Jeffrey D, Reed, George W, Gravallese, Ellen M, Furst, Daniel E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978994/
https://www.ncbi.nlm.nih.gov/pubmed/24485007
http://dx.doi.org/10.1186/ar4469

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978994/
https://www.ncbi.nlm.nih.gov/pubmed/24485007
http://dx.doi.org/10.1186/ar4469

Ejemplares similares